{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003183","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.700674+00:00","generated_at":"2026-05-21T08:39:58.224137+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2","bullets":["Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.","Completed $15M equity financing from institutional investors; cash and equivalents total $13.9M.","EB06 Phase 2 IND submission to FDA expected H2 2025; topline results 12-18 months after clearance.","EB05 ARDS study fully funded by government; R&D spend shifted from EB05 to EB06 program."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003183","json":"https://secwatch.observer/filing/0001171843-25-003183.json","markdown":"https://secwatch.observer/filing/0001171843-25-003183.md","text":"https://secwatch.observer/filing/0001171843-25-003183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325003183/0001171843-25-003183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325003183/f8k_051425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:39:58.224137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}